摘要
在过去的数十年里,大麻体系(包括合成的和内源性的大麻素受体激动剂,他们的受体和降解酶)被证明在动脉粥样硬化和急性心血管疾病中诱导了强大的免疫调节活性。与传统的报道的其他大麻素受体不同,2型大麻素受体(CB2)选择性激活起着抗炎性和动脉粥样硬化血管和下游缺血周边器官中的保护作用。CB2是一类跨膜受体能够触发人类和动脉硬化动物模型心脏、免疫、血管细胞保护性的细胞内通路。考虑到基础研究数据,药物激活CB2在循环或者外周靶细胞的功能,可能是一个抵御动脉硬化的有前景的方法。本综述更新了在动脉粥样硬化和急性缺血性事件不同CB2-触发的通路中的临床前研究的证据。
关键词: 动脉硬化,大麻素受体,2型大麻素受体,缺血/再灌注损伤,缺血性中风。
Current Medicinal Chemistry
Title:Cannabinoid Receptor Type 2 Activation in Atherosclerosis and Acute Cardiovascular Diseases
Volume: 21 Issue: 35
Author(s): Federico Carbone, Francois Mach, Nicolas Vuilleumier and Fabrizio Montecucco
Affiliation:
关键词: 动脉硬化,大麻素受体,2型大麻素受体,缺血/再灌注损伤,缺血性中风。
摘要: In the last decades, the cannabinoid system (comprising synthetic and endogenous cannabinoid agonists and antagonists, their receptors and degrading enzymes) has been shown to induce potent immunomodulatory activities in atherogenesis and acute ischemic complications. Different from the other cannabinoid receptors in which controversial results are reported, the selective activation of the cannabinoid receptor type 2 (CB2) has been shown to play antiinflammatory and protective actions within atherosclerotic vessels and downstream ischemic peripheral organs. CB2 is a transmembrane receptor that triggers protective intracellular pathways in cardiac, immune and vascular cells in both human and animal models of atherosclerosis. Considering basic research data, medications activating CB2 function in the circulation or peripheral target organs might be a promising approach against atherogenesis. This review updates evidence from preclinical studies on different CB2-triggered pathways in atherosclerosis and acute ischemic events.
Export Options
About this article
Cite this article as:
Carbone Federico, Mach Francois, Vuilleumier Nicolas and Montecucco Fabrizio, Cannabinoid Receptor Type 2 Activation in Atherosclerosis and Acute Cardiovascular Diseases, Current Medicinal Chemistry 2014; 21 (35) . https://dx.doi.org/10.2174/0929867321666140915141332
DOI https://dx.doi.org/10.2174/0929867321666140915141332 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The First Line of Defense Against Cardiac Hypertrophy
Current Molecular Medicine Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds Pharmacology of TRP Channels in the Vasculature
Current Vascular Pharmacology Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology Lost in Translation: What is Limiting Cardiomyoplasty and Can Tissue Engineering Help?
Current Stem Cell Research & Therapy Calcium Handling and Arrhythmogenesis
Medicinal Chemistry Mitochondrial Dysfunctions in Bipolar Disorder: Effect of the Disease and Pharmacotherapy
CNS & Neurological Disorders - Drug Targets Ranolazine and its Antiarrhythmic Actions
Cardiovascular & Hematological Agents in Medicinal Chemistry Approaches Used in Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy
Current Cancer Drug Targets S100A1: Structure, Function, and Therapeutic Potential
Current Chemical Biology Current Status of Therapeutic Angiogenesis with Protein, Gene and Cell Therapy
Current Drug Therapy The Mechanism of Dead-in-Bed Syndrome and Other Sudden Unexplained Nocturnal Deaths
Current Diabetes Reviews Cardiac Aging and Insulin Resistance: Could Insulin/Insulin-Like Growth Factor (IGF) Signaling be used as a Therapeutic Target?
Current Pharmaceutical Design The GH/IGF-1 Axis in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Mitochondrial Dysfunction in Heart Failure and Potential Therapeutic Targets
Current Pharmaceutical Design The Role of Adipokines in Hypertension and Cardiovascular Disease
Current Hypertension Reviews Heart Disease Induced by AAS Abuse, Using Experimental Mice/Rats Models and the Role of Exercise-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry Sex Differences in Biomarkers for Predicting Cardiovascular and Coronary Events
Current Vascular Pharmacology General Aspects of Metal Toxicity
Current Medicinal Chemistry